Kip Harry Life Science Professional
Join a focused discussion group on the therapeutic potential of lncRNA, addressing the following questions:
Have exomes and RNA-Seq hindered, rather than helped, lncRNA disease genomics?
How can we proceed from disease lncRNA discovery, in GWAS and functional studies, to translational therapeutics?
Which of the currently known lncRNA mechanisms present the best opportunities for therapeutic targeting?
What are the limitations of animal models for studying lncRNA function, in view of lncRNA evolutionary non-conservation?
In the absence of a “national institute of RNA” or lncRNA study sections at the NIH, can pharmaceutical companies drive clinical-translational work in this field through academic-industry partnerships?
For more information, see here: http://bit.ly/17vTFxF